Global Cancer Vaccines Market - Forecasts from 2018 to 2023

Global Cancer Vaccines Market - Forecasts from 2018 to 2023

The global cancer vaccines market is projected to grow at a CAGR of XX.XX% to reach US$XX.XXX billion by 2023, from US$XX.XXX billion in 2017. Cancer vaccines are either used to protect against cancer or provide treatment. Hence, they are categorized into two types namely prevention and treatment. The growing incidences of cancers worldwide are one of the major market drivers driving the growth of the global cancer vaccines market in the forecast period. Cancer Vaccines are approved for Hepatitis B (HBV) and Human Papilloma Virus (HPV) by FDA. The growing aging population globally may, however, hamper the market growth due to the weak immune system of the elderly population, there are chances where they may be unable to produce an immune response after vaccination.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global cancer vaccines value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global cancer vaccines market.

Major industry players profiled as part of the report are AstraZeneca, GlaxoSmithKline plc., Merck & Co., Inc., Pfizer Inc. and Sanofi among others.

Segmentation

The global cancer vaccines market has been analyzed through following segments:

By Type

Prevention

Treatment

 

By Application

Cervical Cancer

Prostate Cancer

Others

 

By Geography

North America

USA

Canada

Mexico

Others

 

South America

Brazil

Argentina

Others

 

Europe

Germany

France

United Kingdom

Spain

Others

 

Middle East and Africa

Saudi Arabia

Israel

Others

 

Asia Pacific

China

Japan

South Korea

India

Others

 

Target audience

Manufacturers

Suppliers

Distributors

Service Providers

Government Agencies

Research Organizations

Consultants

 

Key insights offered

What will be the global cancer vaccines market size from 2017 to 2023?

How are the major drivers and restraints affecting the global cancer vaccines market growth and the opportunities which exist for key vendors?

Which segment and region will drive or lead the market growth and why?

A comprehensive analysis of competitive landscape and key market participants’ behaviour

Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth.

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY  
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. GLOBAL CANCER VACCINES MARKET BY TYPE
5.1. Prevention
5.2. Treatment
6. GLOBAL CANCER VACCINES MARKET BY APPLICATION
6.1. Cervical Cancer
6.2. Prostate Cancer
6.3. Others
7. GLOBAL CANCER VACCINES MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentia
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1.  Market Share of Key Players
8.2.  Recent Investment and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. AstraZeneca
9.1.1. Company Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. GlaxoSmithKline plc.
9.2.1. Company Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Recent Developments
9.3.  Merck & Co., Inc.
9.3.1. Company Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. Pfizer Inc.
9.4.1. Company Overview
9.4.2. Financials
9.4.3. Products and Services
9.4.4. Recent Developments
9.5.  Sanofi
9.5.1. Company Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. Bristol-Myers Squibb
9.6.1. Company Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. Moderna, Inc.
9.7.1. Company Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. OncBioMune Pharmaceuticals Inc.
9.8.1. Company Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. MaxiVAX
9.9.1. Company Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. Nouscom
9.10.1. Company Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Recent Developments
LIST OF FIGURES
LIST OF TABLES
DISCLAIMER 

AstraZeneca

GlaxoSmithKline plc.

Merck & Co., Inc.

Pfizer Inc.

Sanofi

Bristol-Myers Squibb

Moderna, Inc.

OncBioMune Pharmaceuticals Inc.

MaxiVAX

Nouscom

  • SKU:
  • Publishing Date: 2018-11-23
  • Product Code: 1
  • Availability: In Stock
  • $3,800.00
  • Ex Tax: $3,800.00

Available Options